You are currently viewing the summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Summary
A new class of anti-HIV drugs called protease inhibitors offers the most promising therapy so far. In combination with other antiviral drugs, they can reduce virus loads to undetectable levels. The manufacturers of the two leading protease inhibitors, Merck and Abbott, took different routes but arrived at the finishing post at almost exactly the same time.











